IL25 and neoplasm: In the research conducted by Mombelli et al., studying the signaling pathways that activate IL-17A and IL-17 E in breast cancer cells using the method of reverse transcription coupled with quantitative polymerase chain reaction (RT qPCR), the expression of IL-17RA/RC and IL-17RA receptors was significantly higher in tumor than in normal breast tissue, backing the presence of active IL-17A and IL-17E signaling in breast cancer cells (22).